Long non-coding RNA HSAT II as a new biomarker for the identification of high risk intraductal papillary mucinous neoplasms (IPMNs).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e15246-e15246
Author(s):  
Francesco Pantano ◽  
Giuseppe Perrone ◽  
Bruno Vincenzi ◽  
Michele Iuliani ◽  
Marco Fioramonti ◽  
...  
Keyword(s):  
High Risk ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Non Coding Rna ◽  
Mucinous Neoplasms ◽  
Long Non Coding Rna

Possibility of detecting intraductal papillary mucinous neoplasms using metabolite biomarkers for pancreatic cancer

2020 ◽  
Vol 14 (11) ◽  
pp. 1009-1020
Author(s):  
Ryota Nakano ◽  
Shin Nishiumi ◽  
Takashi Kobayashi ◽  
Takuya Ikegawa ◽  
Yuzo Kodama ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
High Risk ◽  
Multiple Logistic Regression Analysis ◽  
High Sensitivity ◽  
Plasma Samples ◽  
Multiple Logistic Regression ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Detection Model ◽  
High Risk Factors ◽  
Mucinous Neoplasms

Aim: The aim of this study was to identify whether metabolite biomarker candidates for pancreatic cancer (PC) could aid detection of intraductal papillary mucinous neoplasms (IPMN), recognized as high-risk factors for PC. Materials & methods: The 12 metabolite biomarker candidates, which were found to be useful to detect PC in our previous study, were evaluated for plasma samples from patients with PC (n = 44) or IPMN (n = 24) or healthy volunteers (n = 46). Results: Regarding the performance of individual biomarkers of PC and PC high-risk IPMN, lysine exhibited the best performance (sensitivity: 67.8%; specificity: 86.9%). The multiple logistic regression analysis-based detection model displayed high sensitivity and specificity values of 92.5 and 90.6%, respectively. Conclusion: Metabolite biomarker candidates for PC are useful for detecting high-risk IPMN, which can progress to PC.

Patients with pancreatic intraductal papillary mucinous neoplasms are at high risk of colorectal cancer development

Surgery ◽  
2006 ◽  
Vol 139 (6) ◽  
pp. 749-754 ◽  
Author(s):  
H EGUCHI ◽  
O ISHIKAWA ◽  
H OHIGASHI ◽  
Y TOMIMARU ◽  
Y SASAKI ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
High Risk ◽  
Cancer Development ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Mucinous Neoplasms

Noninvasive Discrimination of Low and High-risk Pancreatic Intraductal Papillary Mucinous Neoplasms

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Susanne Roth ◽  
Promita Bose ◽  
Mohamed S. S. Alhamdani ◽  
Shakhawan A. Mustafa ◽  
Christine Tjaden ◽  
...  
Keyword(s):  
High Risk ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Mucinous Neoplasms

scholarly journals Immunoautophagy-Related Long Noncoding RNA (IAR-lncRNA) Signature Predicts Survival in Hepatocellular Carcinoma

Biology ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 1301
Author(s):  
Yulu Wang ◽  
Fangfang Ge ◽  
Amit Sharma ◽  
Oliver Rudan ◽  
Maria F. Setiawan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
High Risk ◽  
Immune Cells ◽  
Clinical Characteristics ◽  
Cox Regression ◽  
Pearson Correlation ◽  
Clinical Samples ◽  
Special Role ◽  
Non Coding Rna ◽  
Long Non Coding Rna

Background: The dysregulation of autophagy and immunological processes has been linked to various pathophysiological conditions, including cancer. Most notably, their particular involvement in hepatocellular carcinoma (HCC) is becoming increasingly evident. This has led to the possibility of developing a prognostic signature based on immuno-autophagy-related (IAR) genes. Given that long non-coding RNAs (lncRNAs) also play a special role in HCC, a combined signature utilizing IAR genes and HCC-associated long noncoding RNAs (as IARlncRNA) may potentially help in the clinical scenario. Method: We used Pearson correlation analysis, Kaplan–Meier survival curves, univariate and multivariate Cox regression, and ROC curves to generate and validate a prognostic immuno-autophagy-related long non-coding RNA (IARlncRNA) signature. The Chi-squared test was utilized to investigate the correlation between the obtained signature and the clinical characteristics. CIBERSORT algorithms and the Wilcoxon rank sum test were applied to investigate the correlation between signature and infiltrating immune cells. GO and KEGG analyses were performed to derived signature-dependent pathways. Results: Herein, we build an IAR-lncRNA signature (as first in the literature) and demonstrate its prognostic ability in hepatocellular carcinoma. Primarily, we identified three IARlncRNAs (MIR210HG, AC099850.3 and CYTOR) as unfavorable prognostic determinants. The obtained signature predicted the high-risk HCC group with shorter overall survival, and was further associated with clinical characteristics such as tumor grade (t = 10.918, p = 0.001). Additionally, several infiltrating immune cells showed varied fractions between the low-risk group and the high-risk HCC groups in association with the obtained signature. In addition, pathways analysis described by the signature clearly distinguishes both risk groups in HCC. Conclusions: The immuno-autophagy-related long non-coding RNA (IARlncRNA) signature we established exhibits a prognostic ability in hepatocellular carcinoma. To our knowledge, this is the first attempt in the literature to combine three determinants (immune, autophagy and LnRNAs), thus requiring molecular validation of this obtained signature in clinical samples.

scholarly journals Risk Factors for Development of High-Risk Stigmata in Branch-Duct Intraductal Papillary Mucinous Neoplasms

2020 ◽  
Author(s):  
Tatasuhiro Yamazaki ◽  
Takeshi Tomoda ◽  
Hironari Kato ◽  
Kazuyuki Miyamoto ◽  
Akihiro Matsumi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Growth Rate ◽  
High Risk ◽  
Odds Ratio ◽  
Imaging Studies ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Branch Duct ◽  
Mucinous Neoplasms ◽  
Cyst Growth

Abstract Background: Strict follow-up is recommended for branch-duct intraductal papillary mucinous neoplasms (BD-IPMN) to avoid missing the development of high-risk stigmata (HRS) at a premalignant stage. This study aimed to identify the risk factors associated with the development of HRS during follow-up.Methods: We performed a retrospective analysis of 283 patients with BD-IPMN, treated at the Okayama University Hospital in Japan between January 2009 and December 2016. Only patients with imaging studies indicative of classical features of BD-IPMN without HRS and followed for >1 year were included in the study. We performed radiological follow-up every 6 months and collected patients’ demographic data, cyst characteristics, and clinical outcomes. Cyst size was recorded at the initial and final imaging studies and growth rate was calculated. The primary outcome was to evaluate the risk factors for development of HRS in patients with BD-IPMN without HRS at the initial diagnosis.Results: Patients with BD-IPMN had a median follow-up of 53.3 months. Based on image analyses, a mean cysts size were initially 18.0 mm and their final size was 20.4 mm, and the mean annual cyst growth was 0.57 mm. Among them, 10 patients (3.5%) developed HRS after a median surveillance period of 55.8 months. Main pancreatic duct (MPD) size (5-9 mm) and cyst growth rate (>2.5 mm/year) were, both, independent risk factors for the development of HRS (odds ratio, 14.2; 95% CI, 3.1-65.2, P = .0006, and odds ratio, 6.1; 95% CI 1.5-25.5, P = .014). Considering the number of worrisome features (WFs), the rate of HRS development was not a WF: 2.0% (4/199), a single WF: 1.6% (1/62), multiple WFs: 22.7% (5/22), and significantly higher in multiple WFs (95% CI: 4.0–57.1; p=.0003).Conclusions: MPD dilation, rapid cyst growth, and multiple WFs were significant risk factors for the development of HRS. In the presence of such features, it is necessary to closely follow the development of HRS and avoid missing the best opportunity for surgical intervention.

scholarly journals Inflammation-Related Long Non-Coding RNA Signature Predicts the Prognosis of Gastric Carcinoma

2021 ◽  
Vol 12 ◽  
Author(s):  
ShuQiao Zhang ◽  
XinYu Li ◽  
ChunZhi Tang ◽  
WeiHong Kuang
Keyword(s):  
High Risk ◽  
Gastric Carcinoma ◽  
Risk Groups ◽  
Cytolytic Activity ◽  
Immune Checkpoints ◽  
Type I ◽  
Kaplan Meier ◽  
Non Coding Rna ◽  
Prognostic Prediction ◽  
Long Non Coding Rna

Background: Gastric carcinoma (GC) is a molecularly and phenotypically highly heterogeneous disease, making the prognostic prediction challenging. On the other hand, Inflammation as part of the active cross-talk between the tumor and the host in the tumor or its microenvironment could affect prognosis.Method: We established a prognostic multi lncRNAs signature that could better predict the prognosis of GC patients based on inflammation-related differentially expressed lncRNAs in GC.Results: We identified 10 differently expressed lncRNAs related to inflammation associated with GC prognosis. Kaplan-Meier survival analysis demonstrated that high-risk inflammation-related lncRNAs signature was related to poor prognosis of GC. Moreover, the inflammation-related lncRNAs signature had an AUC of 0.788, proving their utility in predicting GC prognosis. Indeed, our risk signature is more precise in predicting the prognosis of GC patients than traditional clinicopathological manifestations. Immune and tumor-related pathways for individuals in the low and high-risk groups were further revealed by GSEA. Moreover, TCGA based analysis revealed significant differences in HLA, MHC class-I, cytolytic activity, parainflammation, co-stimulation of APC, type II INF response, and type I INF response between the two risk groups. Immune checkpoints revealed CD86, TNFSF18, CD200, and LAIR1 were differently expressed between lowand high-risk groups.Conclusion: A novel inflammation-related lncRNAs (AC015660.1, LINC01094, AL512506.1, AC124067.2, AC016737.1, AL136115.1, AP000695.1, AC104695.3, LINC00449, AC090772.1) signature may provide insight into the new therapies and prognosis prediction for GC patients.

Sign in / Sign up

Export Citation Format

Share Document